ClinicalTrials.gov
ClinicalTrials.gov Menu

Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01151085
Recruitment Status : Completed
First Posted : June 25, 2010
Results First Posted : August 8, 2013
Last Update Posted : August 8, 2013
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
To collect the efficacy and safety informations of voriconazole related to their appropriate use in daily practice.

Condition or disease Intervention/treatment
Systemic Mycosis Drug: Voriconazole

Detailed Description:
All the subjects whom an investigator prescribes the first voriconazole (VFEND) should be registered consecutively until the number of subjects reaches target number in order to extract subjects enrolled into the investigation at random.

Study Type : Observational
Actual Enrollment : 1002 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Vfend Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Study Start Date : April 2006
Actual Primary Completion Date : May 2012
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Voriconazole
Subjects who are treated with voriconazole
Drug: Voriconazole

Voriconazole Intravenous Solution 200 mg:

Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.

Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:

administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.

Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.

However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.

In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.

Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.

Other Name: VFEND for Intravenous Use, Voriconazole for Intravenous Use, VFEND Tablets, Voriconazole Tablet



Primary Outcome Measures :
  1. Number of Participants With the Frequency of Treatment Related Adverse Events. [ Time Frame: 16 weeks ]
    Adverse events mean all unfavorable events that occur in participants after administration of Voriconazole, irrespective of causal relationship to Voriconazole (including clinically problematic abnormal changes in laboratory test values). Treatment related Adverse Events were evaluated in company with the causal relationship to Voriconazole.

  2. Number of Participants That Responded to Voriconazole Treatment. [ Time Frame: 16 weeks ]
    The primary endpoint was the efficacy ratio (number of effective cases/number of evaluable cases for efficacy assessment) among the cohort comprising the subjects for efficacy analysis.


Secondary Outcome Measures :
  1. Number of Unlisted Treatment Related Adverse Events in Japanese Package Insert. [ Time Frame: 16 weeks ]
    Adverse events mean all unfavorable events that occur in participants after administration of Voriconazole, irrespective of causal relationship to Voriconazole (including clinically problematic abnormal changes in laboratory test values). Number of Treatment Related Adverse Events were evaluated in company with the causal relationship to Voriconazole. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction in Japanese package insert.

  2. Risk Factors for the Frequency of Treatment Related Adverse Events -Gender. [ Time Frame: 16 weeks ]
    Number of participants with Treatment Related Adverse Events of Voriconazole to determine whether male or female is significant risk factor.

  3. Risk Factors for the Frequency of Treatment Related Adverse Events -Severity of Infections. [ Time Frame: 16 weeks ]
    Number of participants with Treatment Related Adverse Events of Voriconazole to determine whether severity of infections(mild, moderate or severe) is significant risk factor.

  4. Risk Factors for the Frequency of Treatment Related Adverse Events -Past History. [ Time Frame: 16 weeks ]
    Number of participants with Treatment Related Adverse Events of Voriconazole to determine whether with or without Past History is significant risk factor.

  5. Number of Participants That Responded to Voriconazole Treatment -Severity of Infections. [ Time Frame: 16 weeks ]
    Number of participants that responded to voriconazole to determine whether severity of infections(mild, moderate or severe) is significant risk factor.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The patients whom an investigator involving A1501076 prescribes the voriconazole (VFEND).
Criteria

Inclusion Criteria:

  • Male or Female subjects intend to treat their deep mycosis who are prescribed voriconazole (VFEND) by their Physicians.

Exclusion Criteria:

  • Subject who heve been prescribed voriconazole (VFEND) before.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01151085


Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01151085     History of Changes
Other Study ID Numbers: A1501076
First Posted: June 25, 2010    Key Record Dates
Results First Posted: August 8, 2013
Last Update Posted: August 8, 2013
Last Verified: May 2013

Keywords provided by Pfizer:
Systemic Mycosis
Aspergillus infection
Candidiasis
Cryptococcal infections
Japanese
voriconazole
VFEND
Regulatory Post Marketing Commitment Plan.

Additional relevant MeSH terms:
Mycoses
Voriconazole
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors